Please login to the form below
Norbert Bischofberger
This page shows the latest Norbert Bischofberger news and features for those working in and with pharma, biotech and healthcare.
Genentech and Kronos Bio announce oncology partnership worth over $570m
The collaboration is the first for Kronos, according to the company's president and chief executive officer, Norbert Bischofberger, who said the partnership brought together expertise from both companies “with the ... We are pleased to be able to
Latest news
-
Daily Brief: another departure at Gilead, veteran researcher to head up Karuna
In April, longstanding chief scientific officer Norbert Bischofberger also left the company for a new venture.
-
Amgen’s R&D chief Sean Harper retires to seek biotech post
for a smaller player he’s following in the footsteps of Gilead’s former R&D head Norbert Bischofberger, who resigned to join start-up Kronos Bio earlier this year.
-
Long-serving R&D head Bischofberger to leave Gilead
Gilead’s long-serving head of R&D Norbert Bischofberger will step down from his position at the end of April to be replaced by John McHutchison, currently executive vice president ... As it stands there is no word of what Bischofberger plans to do next,
-
Gilead's Hepatitis B therapy Vemlidy granted EU approval
Dr Norbert Bischofberger, chief scientific officer and executive vice president of R&D at Gilead, said: “TAF reflects Gilead's ongoing commitment to improve and simplify care for people with chronic
-
Gilead files hepatitis C salvage regimen in US
chief scientific officer Norbert Bischofberger.
More from news
Approximately 1 fully matching, plus 16 partially matching documents found.
Latest appointments
-
Gilead makes senior changes
Norbert Bischofberger, the company's chief scientific officer, said: “Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
CHASE
We are a leading provider of outsourced commercial, medical and recruitment services to UK pharmaceutical, biotech and healthcare companies....
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
